Enterome Building A Microbiome R&D Presence Via Pharma Deals
Executive Summary
The number of microbiome-based companies is growing with scientific breakthroughs in this area. Pierre Belichard, CEO of the French gut microbiome focused company Enterome, talked to Scrip at the Biotrinity 2017 meeting in London about its partnerships, pipeline progress and his plans for the future.
You may also be interested in...
Nestlé's Microbiome Interest Deepens With Enterome JV
Nestlé Health Science has invested $23m in a joint venture it is setting up with French microbiome company Enterome. Microbiome Diagnostics Partners (MDP) will be focused on developing microbiome-based diagnostics for the assessment and management of irritable bowel disorder and liver diseases.
Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
Takeda And Enterome To Jointly Mine The Microbiome
In a deal that further expands its credentials, French company Enterome has inked an alliance with Japan's Takeda to conduct research and develop novel therapeutics aimed at microbiome targets thought to play crucial roles in gastrointestinal disorders.